当前位置:
X-MOL 学术
›
Diabetes Obes. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2021-08-16 , DOI: 10.1111/dom.14518 Philip D Home 1 , Roopa Mehta 2 , Khadija A S Hafidh 3 , Olesya Y Gurova 4 , Agustina Alvarez 5 , Paul Serafini 6 , Mir-Masoud Pourrahmat 6
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2021-08-16 , DOI: 10.1111/dom.14518 Philip D Home 1 , Roopa Mehta 2 , Khadija A S Hafidh 3 , Olesya Y Gurova 4 , Agustina Alvarez 5 , Paul Serafini 6 , Mir-Masoud Pourrahmat 6
Affiliation
To assess the efficacy and safety of iGlarLixi, a fixed-ratio combination of basal insulin glargine 100 U/mL and lixisenatide (glucagon-like peptide-1 receptor agonist) versus IDegAsp, a co-formulation of basal insulin degludec 100 U/mL with rapid-acting insulin aspart.
中文翻译:
iGlarLixi 与 IDegAsp 的疗效和安全性:系统文献回顾和间接治疗比较的结果
为了评估 iGlarLixi 的疗效和安全性,基础甘精胰岛素 100 U/mL 和 lixisenatide(胰高血糖素样肽 1 受体激动剂)与 IDegAsp(基础德谷胰岛素 100 U/mL 与速效门冬胰岛素。
更新日期:2021-08-16
中文翻译:
iGlarLixi 与 IDegAsp 的疗效和安全性:系统文献回顾和间接治疗比较的结果
为了评估 iGlarLixi 的疗效和安全性,基础甘精胰岛素 100 U/mL 和 lixisenatide(胰高血糖素样肽 1 受体激动剂)与 IDegAsp(基础德谷胰岛素 100 U/mL 与速效门冬胰岛素。